These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 8695873

  • 1. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
    Molineux G, Hartley CA, McElroy P, McCrea C, McNiece IK.
    Blood; 1996 Aug 15; 88(4):1509-14. PubMed ID: 8695873
    [Abstract] [Full Text] [Related]

  • 2. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA, Marzec UM, Kelly AB, Cheung E, Tomer A, Nichol JL, Hanson SR, Stead RB.
    Blood; 1997 Jan 01; 89(1):155-65. PubMed ID: 8978288
    [Abstract] [Full Text] [Related]

  • 3. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.
    Blood; 1996 Jul 15; 88(2):511-21. PubMed ID: 8695799
    [Abstract] [Full Text] [Related]

  • 4. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K, Akahori H, Takahashi K, Tahara E, Kato T, Miyazaki H.
    Blood; 1998 Jan 01; 91(1):37-45. PubMed ID: 9414267
    [Abstract] [Full Text] [Related]

  • 5. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK.
    Blood; 1996 Jul 01; 88(1):366-76. PubMed ID: 8704197
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H, Shibuya K, Ozai M, Ida M, Kabaya K, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov 01; 14(6):678-89. PubMed ID: 8948025
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Harada M.
    Bone Marrow Transplant; 2001 Aug 01; 28(4):329-34. PubMed ID: 11571503
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM, MacVittie TJ, Roskos L, Stead RB.
    Stem Cells; 2003 Aug 01; 21(1):79-89. PubMed ID: 12529554
    [Abstract] [Full Text] [Related]

  • 17. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
    Harada K, Ide Y, Tazunoki Y, Imai A, Yanagida M, Kikuchi Y, Imai A, Ishii H, Kawahara J, Izumi H, Kusaka M, Tokiwa T.
    J Pharm Pharmacol; 1999 Jul 01; 51(7):841-6. PubMed ID: 10467960
    [Abstract] [Full Text] [Related]

  • 18. Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors.
    Liu Yin JA, Adams JA, Brereton ML, Hann A, Harrison BD, Briggs M.
    Br J Haematol; 2000 Mar 01; 108(4):743-6. PubMed ID: 10792278
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG.
    Blood; 1997 May 01; 89(9):3118-28. PubMed ID: 9129014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.